CytoMed Therapeutics Limited Expense From Share-based Payment Transactions In Which Goods Or Services Received Did Not Qualify For Recognition As Assets
CytoMed Therapeutics Limited (GDTC) reported Expense From Share-based Payment Transactions In Which Goods Or Services Received Did Not Qualify For Recognition As Assets of SGD 1.22 million for the 12-month period ending 2022-12-31, per its 20-F filed 2024-04-22.
Discontinued › Expense Statement › Operating Expenses
ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets · last filed 2024-04-22
| Period end | Expense From Share-based Payment Transactions In Which Goods Or Services Received Did Not Qualify For Recognition As Assets 12 month |
|---|---|
| 2022-12-31 | 1.22M SGD 20-F · filed 2024-04-22 |
| 2021-12-31 | 2.00M SGD 20-F · filed 2023-05-01 |
| 2020-12-31 | 500.00K SGD 20-F · filed 2023-05-01 |